Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (341-350 of 442) with videos related to

Pageof 45
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2015
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with MelanomaDavid S Hong, Razelle Kurzrock, Jennifer J Wheler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancerRazelle Kurzrock, Steven I Sherman, Douglas W Ball, et al.
Investigational New Drugs|October 28, 2017
Radiomics to predict immunotherapy-induced pneumonitis: proof of conceptRivka R Colen, Takeo Fujii, Mehmet Asim Bilen, et al.
JCO Precision Oncology|September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional IndicationsEcaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
NPJ Precision Oncology|April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignanciesOmar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
The Journal of Investigative Dermatology|February 26, 2019
Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic MelanomaMeredith McKean, Junna Oba, Junsheng Ma, et al.
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget|April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unitDenis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
The New England Journal of Medicine|May 6, 2026
Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic CancerBrian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, et al.
Pageof 45

Showing results (341-350 of 442) with videos related to

Sort By:
Pageof 45
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2015
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with MelanomaDavid S Hong, Razelle Kurzrock, Jennifer J Wheler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancerRazelle Kurzrock, Steven I Sherman, Douglas W Ball, et al.
Investigational New Drugs|October 28, 2017
Radiomics to predict immunotherapy-induced pneumonitis: proof of conceptRivka R Colen, Takeo Fujii, Mehmet Asim Bilen, et al.
JCO Precision Oncology|September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional IndicationsEcaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
NPJ Precision Oncology|April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignanciesOmar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
The Journal of Investigative Dermatology|February 26, 2019
Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic MelanomaMeredith McKean, Junna Oba, Junsheng Ma, et al.
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget|April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unitDenis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
The New England Journal of Medicine|May 6, 2026
Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic CancerBrian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, et al.
Pageof 45